Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Castleman Disease | Research

IL-6 expression helps distinguish Castleman’s disease from IgG4-related disease in the lung

Authors: Yasuhiro Kinugawa, Takeshi Uehara, Mai Iwaya, Shiho Asaka, Shota Kobayashi, Tomoyuki Nakajima, Masamichi Komatsu, Masanori Yasuo, Hiroshi Yamamoto, Hiroyoshi Ota

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

It is difficult to distinguish between multicentric Castleman’s disease (MCD) and IgG4-related lung disease (IgG4-LD), an IgG4-related disease (IgG4-RD) in the lung.

Methods

We focused on IL-6, which is elevated in MCD, to distinguish between MCD and IgG4-LD by RNAscope, a highly sensitive RNA in situ method. Six cases of MCD and four cases of IgG4-LD were selected.

Results

In all cases of MCD and IgG4-LD, 10 or more IgG4-positive cells were found in one high-power field. All MCD cases were inconsistent with the pathological IgG4-related comprehensive diagnostic criteria, but 2 of 6 cases had an IgG4/IgG ratio greater than 40%. In all IgG4-LD cases, histological features were consistent with the pathological IgG4-RD comprehensive diagnostic criteria. IL-6 expression was observed in all MCD and IgG4-LD cases except for one IgG4-LD biopsy. IL-6-expressing cells were mainly identified in the stroma. Sites of IL-6 expression were not characteristic and were sparse. IL-6 expression tended to be higher in MCD compared with IgG4-LD. A positive correlation was found between the IL-6 H-score and serum IL-6 level.

Conclusion

Differences in IL-6 expression may help distinguish between MCD and IgG4-LD. In addition, the presence of high IL-6 levels may help elucidate the pathological mechanisms of IgG4-LD.
Literature
1.
go back to reference Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol. 2011;23:108–13.CrossRef Sah RP, Chari ST. Serologic issues in IgG4-related systemic disease and autoimmune pancreatitis. Curr Opin Rheumatol. 2011;23:108–13.CrossRef
2.
go back to reference Yamamoto M, Takahashi H, Suzuki C, Tabeya T, Ohara M, Naishiro Y, et al. Analysis of serum IgG subclasses in Churg-Strauss syndrome–the meaning of elevated serum levels of IgG4. Intern Med. 2010;49:1365–70.CrossRef Yamamoto M, Takahashi H, Suzuki C, Tabeya T, Ohara M, Naishiro Y, et al. Analysis of serum IgG subclasses in Churg-Strauss syndrome–the meaning of elevated serum levels of IgG4. Intern Med. 2010;49:1365–70.CrossRef
3.
go back to reference Dhall D, Suriawinata AA, Tang LH, Shia J, Klimstra DS. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Hum Pathol. 2010;41:643–52.CrossRef Dhall D, Suriawinata AA, Tang LH, Shia J, Klimstra DS. Use of immunohistochemistry for IgG4 in the distinction of autoimmune pancreatitis from peritumoral pancreatitis. Hum Pathol. 2010;41:643–52.CrossRef
4.
go back to reference Chen LYC, Mattman A, Seidman MA. Carruthers MN IgG4-related disease: what a hematologist needs to know. Haematologica. 2019;104:444–55.CrossRef Chen LYC, Mattman A, Seidman MA. Carruthers MN IgG4-related disease: what a hematologist needs to know. Haematologica. 2019;104:444–55.CrossRef
5.
go back to reference Izumi Y, Takeshita H, Moriwaki Y, Hisatomi K, Matsuda M, Yamashita N, et al. Multicentric Castleman disease mimicking IgG4-related disease: a case report. Mod Rheumatol. 2017;27:174–7.CrossRef Izumi Y, Takeshita H, Moriwaki Y, Hisatomi K, Matsuda M, Yamashita N, et al. Multicentric Castleman disease mimicking IgG4-related disease: a case report. Mod Rheumatol. 2017;27:174–7.CrossRef
6.
go back to reference Sato Y, Kojima M, Takata K, Morito T, Mizobuchi K, Tanaka T, et al. Multicentric Castleman’s disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol. 2010;63:1084–9.CrossRef Sato Y, Kojima M, Takata K, Morito T, Mizobuchi K, Tanaka T, et al. Multicentric Castleman’s disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases. J Clin Pathol. 2010;63:1084–9.CrossRef
7.
go back to reference Otani K, Inoue D, Fujikura K, Komori T, Abe-Suzuki S, Tajiri T, et al. Idiopathic multicentric Castleman’s disease: a clinicopathologic study in comparison with IgG4-related disease. Oncotarget. 2018;9:6691–706.CrossRef Otani K, Inoue D, Fujikura K, Komori T, Abe-Suzuki S, Tajiri T, et al. Idiopathic multicentric Castleman’s disease: a clinicopathologic study in comparison with IgG4-related disease. Oncotarget. 2018;9:6691–706.CrossRef
8.
go back to reference Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21–30.CrossRef Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, Saeki T, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012;22:21–30.CrossRef
9.
go back to reference Matsui S, Yamamoto H, Minamoto S, Waseda Y, Mishima M, Kubo K. Proposed diagnostic criteria for IgG4-related respiratory disease. Respir Investig. 2016;54:130–2.CrossRef Matsui S, Yamamoto H, Minamoto S, Waseda Y, Mishima M, Kubo K. Proposed diagnostic criteria for IgG4-related respiratory disease. Respir Investig. 2016;54:130–2.CrossRef
10.
go back to reference Nakajima T, Uehara T, Maruyama Y, Iwaya M, Kobayashi Y, Ota H. Distribution of Lgr5-positive cancer cells in intramucosal gastric signet-ring cell carcinoma. Pathol Int. 2016;66:518–23.CrossRef Nakajima T, Uehara T, Maruyama Y, Iwaya M, Kobayashi Y, Ota H. Distribution of Lgr5-positive cancer cells in intramucosal gastric signet-ring cell carcinoma. Pathol Int. 2016;66:518–23.CrossRef
11.
go back to reference Zoshima T, Yamada K, Hara S, Mizushima I, Yamagishi M, Harada K, et al. Multicentric Castleman disease with tubulointerstitial nephritis mimicking IgG4-related disease: two case reports. Am J Surg Pathol. 2016;40:495–501.CrossRef Zoshima T, Yamada K, Hara S, Mizushima I, Yamagishi M, Harada K, et al. Multicentric Castleman disease with tubulointerstitial nephritis mimicking IgG4-related disease: two case reports. Am J Surg Pathol. 2016;40:495–501.CrossRef
12.
go back to reference Ogoshi T, Kido T, Yatera K, Oda K, Kawanami T, Ishimoto H, et al. Assessment of pathologically diagnosed patients with Castleman’s disease associated with diffuse parenchymal lung involvement using the diagnostic criteria for IgG4-related disease. Lung. 2013;191:575–83.CrossRef Ogoshi T, Kido T, Yatera K, Oda K, Kawanami T, Ishimoto H, et al. Assessment of pathologically diagnosed patients with Castleman’s disease associated with diffuse parenchymal lung involvement using the diagnostic criteria for IgG4-related disease. Lung. 2013;191:575–83.CrossRef
13.
go back to reference Terasaki Y, Ikushima S, Matsui S, Hebisawa A, Ichimura Y, Izumi S, et al. Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman’s disease. Histopathology. 2017;70:1114–24.CrossRef Terasaki Y, Ikushima S, Matsui S, Hebisawa A, Ichimura Y, Izumi S, et al. Comparison of clinical and pathological features of lung lesions of systemic IgG4-related disease and idiopathic multicentric Castleman’s disease. Histopathology. 2017;70:1114–24.CrossRef
14.
go back to reference Muzes G, Sipos F, Csomor J, Sreter L. Multicentric Castleman’s disease: a challenging diagnosis. Pathol Oncol Res. 2013;19:345–51.CrossRef Muzes G, Sipos F, Csomor J, Sreter L. Multicentric Castleman’s disease: a challenging diagnosis. Pathol Oncol Res. 2013;19:345–51.CrossRef
15.
go back to reference Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease: Where are we now? Semin Diagn Pathol. 2016;33:294–306.CrossRef Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease: Where are we now? Semin Diagn Pathol. 2016;33:294–306.CrossRef
16.
go back to reference Zongfei J, Rongyi C, Xiaomeng C, Lili M, Lingying M, Xiufang K, et al. In vitro IL-6/IL-6R trans-signaling in fibroblasts releases cytokines that may be linked to the pathogenesis of IgG4-related disease. Front Immunol. 2020;11:1272.CrossRef Zongfei J, Rongyi C, Xiaomeng C, Lili M, Lingying M, Xiufang K, et al. In vitro IL-6/IL-6R trans-signaling in fibroblasts releases cytokines that may be linked to the pathogenesis of IgG4-related disease. Front Immunol. 2020;11:1272.CrossRef
17.
go back to reference Yajima R, Takano K, Konno T, Kohno T, Kaneko Y, Kakuki T, et al. Mechanism of fibrogenesis in submandibular glands in patients with IgG4-RD. J Mol Histol. 2018;49:577–87.CrossRef Yajima R, Takano K, Konno T, Kohno T, Kaneko Y, Kakuki T, et al. Mechanism of fibrogenesis in submandibular glands in patients with IgG4-RD. J Mol Histol. 2018;49:577–87.CrossRef
18.
go back to reference Kong X, Ma L, Ji Z, Dong Z, Zhang Z, Hou J, et al. Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol. 2018;36:62–72.PubMed Kong X, Ma L, Ji Z, Dong Z, Zhang Z, Hou J, et al. Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol. 2018;36:62–72.PubMed
19.
go back to reference Castelino FV, Bain G, Pace VA, Black KE, George L, Probst CK, et al. An autotaxin/lysophosphatidic acid/interleukin-6 amplification loop drives scleroderma fibrosis. Arthritis Rheumatol. 2016;68:2964–74.CrossRef Castelino FV, Bain G, Pace VA, Black KE, George L, Probst CK, et al. An autotaxin/lysophosphatidic acid/interleukin-6 amplification loop drives scleroderma fibrosis. Arthritis Rheumatol. 2016;68:2964–74.CrossRef
20.
go back to reference Tsukuda S, Ikeura T, Ito T, Nakamaru K, Masuda M, Hori Y, et al. Clinical implications of elevated serum interleukin-6 in IgG4-related disease. PLoS ONE. 2020;15:e0227479.CrossRef Tsukuda S, Ikeura T, Ito T, Nakamaru K, Masuda M, Hori Y, et al. Clinical implications of elevated serum interleukin-6 in IgG4-related disease. PLoS ONE. 2020;15:e0227479.CrossRef
21.
go back to reference Post GR, Bell RC, Rjoop A, Lobo RH, Yuan Y, Post SR. Diagnostic utility of interleukin-6 expression by immunohistochemistry in differentiating Castleman disease subtypes and reactive lymphadenopathies. Ann Clin Lab Sci. 2016;46:474–9.PubMed Post GR, Bell RC, Rjoop A, Lobo RH, Yuan Y, Post SR. Diagnostic utility of interleukin-6 expression by immunohistochemistry in differentiating Castleman disease subtypes and reactive lymphadenopathies. Ann Clin Lab Sci. 2016;46:474–9.PubMed
22.
go back to reference Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14:22–9.CrossRef Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn. 2012;14:22–9.CrossRef
23.
go back to reference Ishiyama T, Nakamura S, Akimoto Y, Koike M, Tomoyasu S, Tsuruoka N, et al. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman’s disease. Br J Haematol. 1994;86:483–9.CrossRef Ishiyama T, Nakamura S, Akimoto Y, Koike M, Tomoyasu S, Tsuruoka N, et al. Immunodeficiency and IL-6 production by peripheral blood monocytes in multicentric Castleman’s disease. Br J Haematol. 1994;86:483–9.CrossRef
Metadata
Title
IL-6 expression helps distinguish Castleman’s disease from IgG4-related disease in the lung
Authors
Yasuhiro Kinugawa
Takeshi Uehara
Mai Iwaya
Shiho Asaka
Shota Kobayashi
Tomoyuki Nakajima
Masamichi Komatsu
Masanori Yasuo
Hiroshi Yamamoto
Hiroyoshi Ota
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01603-6

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.